Re-Energize Fontan

Not Applicable

Recruiting

• Conditions: Single-ventricle
• Interventions: Other: Usual Care then Live-Video Supervised Exercise Intervention; Other: Live-Video-Supervised Exercise Intervention

• Registration Number: NCT04195451
• Lead Sponsor: Stanford University

Brief Summary

Survival of children with single ventricles ("half a heart") beyond the neonatal period has increased dramatically with the staged Fontan palliation. Yet, long-term morbidity remains high. By the age of 40, 50% of Fontan patients will have died or undergone heart transplantation. With \>1,000 Fontan palliations performed in the US annually, there is a burgeoning population of Fontan patients at risk for progressive heart failure and death. Factors that contribute to onset and progression of heart failure in Fontan patients remain incompletely understood. However, it is established that Fontan patients have poor exercise capacity, associated with a greater risk of morbidity and mortality, in addition to decreased muscle mass, abnormal muscle function, and endothelial dysfunction contributing to disease progression. In adult patients with two ventricles and heart failure, reduced exercise capacity, muscle mass, and muscle strength are powerful predictors of poor outcomes, and exercise interventions can not only improve exercise capacity and muscle mass, but also reverse endothelial dysfunction. Limited exercise interventions in children with congenital heart disease have demonstrated that exercise is safe and effective; however, these studies have been conducted in small, heterogeneous groups, and most had few Fontan patients. Furthermore, none of these interventions have studied the impact of exercise on muscle mass or mitochondrial function, or endothelial function. The investigators propose a milestone-driven, randomized controlled trial in pediatric Fontan patients to test the hypothesis that a live-video-supervised exercise (aerobic + resistance) intervention will improve cardiac and physical capacity; muscle mass, strength and function; and endothelial function. The investigators' ultimate goal is the translation of this model to clinical application as an "exercise prescription" to intervene early in pediatric Fontan patients and decrease long-term morbidity and mortality.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-12-06
• Study First Submitted QC: 2019-12-09
• Study First Posted: 2019-12-11
• Study Start: 2020-08-06
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-05
• Last Update Posted: 2025-01-07
• Primary Completion: 2026-03-01
• Study Completion: 2026-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• 8-19 years of age
• Fontan palliation
• Ability to fast overnight
• Cardiac clearance to exercise by primary cardiologist
• Presence of an adult at home during exercise sessions for patients <14 years old
• English-speaking patient.

Read More

Exclusion Criteria

• NYHA Class IV (severe heart failure)
• Acute illness within the past three months
• Active protein losing enteropathy (albumin <2.5 mg/dL)
• Implanted pacemaker
• Cognitive delay deemed severe enough to inhibit the ability to follow the exercise

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Live-Video-Supervised Exercise Control Arm	Usual Care then Live-Video Supervised Exercise Intervention	Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
Live Video-Supervised Exercise Intervention Arm	Live-Video-Supervised Exercise Intervention	Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.

Primary Outcome Measures

Name	Time	Method
Change in volume of Oxygen Consumed at Maximal Exertion	Baseline, 3 months, 9 months, 12 months	In Fontan patients, peak VO2 is a powerful predictor of poor outcomes. The subjects will undergo progressive cardiopulmonary exercise testing with continuous monitoring by 12-lead EKG and gas exchange by measuring breath-to-breath ventilation. Exercise capacity will be measured by a cardiopulmonary exercise test to obtain the peak VO2

Trial Locations

Locations (1)

Stanford University, Lucile Packard Children Hospital; 🇺🇸 Palo Alto, California, United States